All In Biotech

Drug Trial Radar · NCT07147959

PET-Based Imaging of Radiolabeled CIT-013

PET-Based Imaging to Evaluate the Distribution of Radiolabeled CIT-013 in Patients With Inflammatory Mediated Immune Disease

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Jan 15, 2026

Primary completion

Jul 15, 2026

Study completion Aug 15, 2026

Sponsor

Lead sponsor
Citryll BVIndustry
Sponsor type
Industry
First posted
Aug 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Inflammatory mediated immune diseases (IMIDs), such as rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), are characterized by chronic inflammation resulting from an aberrant immune response. Recent studies have identified neutrophil extracellular traps (NETs) as key contributors to the pathology of these diseases. CIT-013 is a novel humanized monoclonal antibody designed to inhibit NET release and enhance phagocytosis, offering a new potential therapeutic strategy for RA and HS. Previous clinical trials have demonstrated that CIT-013 is well tolerated in both healthy volunteers and patients with RA, with evidence of reduced NET formation and positive effects in active RA cases. Since NET-related inflammation primarily occurs in local tissues, understanding CIT-013's distribution beyond blood measurements is crucial for evaluating its therapeutic potential. This trial therefore uses radiolabeled CIT-013 and Positron Emission Tomography-Computed Tomography (PET-CT) imaging, along with lymph node biopsies, to evaluate the distribution of CIT-013 and target engagement in patients with IMIDs.

Conditions

  • RA

Interventions

  • [89Zr]Zr-CITDrug

    radiolabelled CIT-013

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Distribution of radiolabeled CIT-013 in patients with IMIDsTime frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NL-01

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.